IDNA
Price
$37.04Alerts
Change
-$0.77 (-2.04%)
Updated
Nov 20, 04:59 PM (EDT)
Net Assets
332.22M
Intraday BUY SELL Signals
XBI
Price
$140.38Alerts
Change
-$3.74 (-2.60%)
Updated
Nov 20, 04:59 PM (EDT)
Net Assets
9.74B
Intraday BUY SELL Signals
Interact to see
Advertisement

IDNA vs XBI

IDNA vs XBI Comparison Chart in %
loading
loading
View a ticker or compare two or three
A.I.Advisor
Oct 21, 2026

Which ETF would AI Choose? iShares Genomics Immunology and Healthcare ETF (IDNA) vs. SPDR S&P Biotech ETF (XBI)

Key Takeaways

  • IDNA targets companies benefiting from genomics, immunology, and bioengineering innovations with a concentrated portfolio of approximately 50 holdings and a higher expense ratio of 0.47%.
  • XBI provides equal-weighted exposure to the U.S. biotechnology sector through roughly 160 holdings, emphasizing broad diversification within biotech and a lower expense ratio of 0.35%.
  • Both ETFs focus on healthcare innovation but differ in geographic scope, with IDNA offering global exposure while XBI remains primarily U.S.-centric.
  • IDNA exhibits higher concentration risk due to larger top holdings, whereas XBI's equal-weight methodology reduces single-stock dominance and supports more balanced sector representation.
  • Structural differences position IDNA as a thematic play on emerging biotech technologies and XBI as a comprehensive vehicle for U.S. biotech market participation.
  • Investors seeking cost efficiency and wider diversification may find XBI more aligned with broad sector exposure, while those prioritizing specific innovation themes may prefer IDNA.

Introduction

Investors evaluating targeted healthcare exposure often compare thematic and sector-specific exchange-traded funds (ETFs) like IDNA and XBI. These funds do not compete directly but instead offer complementary approaches within biotechnology and life sciences. IDNA emphasizes global companies positioned for long-term growth in genomics, immunology, and bioengineering, while XBI delivers broad access to the U.S. biotechnology industry through an equal-weighted index. The comparison helps investors understand differences in strategy, diversification, costs, and positioning amid ongoing innovation in drug development and personalized medicine.

iShares Genomics Immunology and Healthcare ETF (IDNA) Overview

The iShares Genomics Immunology and Healthcare ETF (IDNA) seeks to track the NYSE FactSet Global Genomics and Immuno Biopharma Index. This rules-based, passive strategy selects developed and emerging market companies that may benefit from advancements in genomics, immunology, and bioengineering. The fund typically holds around 50 securities, with significant allocations to health care. Top holdings often include Moderna Inc. (MRNA), Twist Bioscience Corp. (TWST), and Iovance Biotherapeutics Inc. (IOVA), reflecting concentration in innovative biopharmaceutical names. The expense ratio stands at 0.47%. IDNA maintains nearly 100% exposure to the health care sector and features a global footprint with primary weight in the United States and select developed markets. Rebalancing follows the underlying index methodology.

SPDR S&P Biotech ETF (XBI) Overview

The SPDR S&P Biotech ETF (XBI) tracks the S&P Biotechnology Select Industry Index using a passive, equal-weighted approach. This methodology assigns roughly equal importance to U.S. biotechnology companies across market capitalizations, resulting in approximately 160 holdings. Top positions typically represent about 2% each, including names such as Twist Bioscience Corp. (TWST), Moderna Inc. (MRNA), and Natera Inc. (NTRA). The expense ratio is 0.35%. XBI allocates nearly all assets to the biotechnology sub-industry within health care and maintains primarily domestic exposure. Quarterly rebalancing supports the equal-weight structure, promoting broader representation across small-, mid-, and large-cap biotech firms.

Industry and Thematic Backdrop

The biotechnology sector continues to evolve amid advances in gene editing, immunotherapy, and precision medicine. Capital flows into life sciences reflect sustained interest in innovation pipelines, supported by regulatory pathways for novel therapies and potential shifts in interest rate expectations that influence growth-oriented investments. Macroeconomic factors, including research and development spending and clinical trial outcomes, drive sector dynamics. Risks include high development failure rates, patent expirations, and policy changes affecting drug pricing and reimbursement. Both ETFs operate within this environment, where thematic exposure to emerging technologies and broad sector participation respond differently to earnings cycles and capital allocation trends in healthcare.

Performance and Positioning Comparison

In recent market cycles, IDNA's thematic focus has led to distinct volatility patterns tied to developments in genomics and immunology companies, while XBI's equal-weighted construction has provided smoother participation across the broader U.S. biotech landscape. Relative positioning highlights IDNA's sensitivity to innovation milestones and global supply chains versus XBI's alignment with domestic sector rotation and earnings breadth. During periods of biotech strength, XBI's diversification across more holdings has supported consistent exposure, whereas IDNA's concentration amplifies outcomes from select high-conviction names. Both funds exhibit elevated volatility compared to broad market benchmarks due to their healthcare emphasis, with differences stemming from geographic scope and weighting methodologies rather than short-term price fluctuations.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors seeking data-driven insights into ETFs like IDNA and XBI can leverage this platform for efficient discovery.

Tickeron AI Verdict

Based on observable structural factors including lower expense ratio, greater number of holdings, and equal-weighted diversification that reduces concentration risk, Tickeron’s AI would currently assign a higher probabilistic preference to XBI for investors seeking broad U.S. biotech exposure. IDNA offers compelling thematic depth in genomics and immunology but carries higher costs and narrower holdings. The assessment weighs cost efficiency, diversification profile, and sector momentum without constituting investment advice.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

VS
IDNA vs. XBI commentary
Nov 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDNA is a Hold and XBI is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for IDNA with price predictions
Nov 20, 2026

IDNA in downward trend: 10-day moving average crossed below 50-day moving average on November 18, 2026

The 10-day moving average for IDNA crossed bearishly below the 50-day moving average on November 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IDNA as a result. In 81 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

The Moving Average Convergence Divergence Histogram (MACD) for IDNA turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 44 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.

IDNA moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for IDNA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDNA advanced for three days, in 243 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

IDNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 167 of 201 cases where IDNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.

A.I.Advisor
a Summary for XBI with price predictions
Nov 20, 2026

XBI's Stochastic Oscillator is remaining in oversold zone for 4 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +5.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in 295 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XBI as a result. In 82 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for XBI turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 48 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

XBI moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for XBI crossed bearishly below the 50-day moving average on November 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for XBI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

TECHNICAL ANALYSIS
Technical Analysis
IDNAXBI
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 12 days ago
86%
Bullish Trend 12 days ago
90%
Declines
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
89%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement

IDNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDNA has been loosely correlated with FATE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if IDNA jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDNA
1D Price
Change %
IDNA100%
-2.14%
FATE - IDNA
57%
Loosely correlated
-9.01%
DNA - IDNA
56%
Loosely correlated
-9.02%
SANA - IDNA
51%
Loosely correlated
-8.62%
BNGO - IDNA
51%
Loosely correlated
-7.10%
ABUS - IDNA
51%
Loosely correlated
-1.23%
More

XBI and

Correlation & Price change

A.I.dvisor indicates that over the last year, XBI has been loosely correlated with RCUS. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if XBI jumps, then RCUS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XBI
1D Price
Change %
XBI100%
-2.73%
RCUS - XBI
60%
Loosely correlated
-1.01%
VYGR - XBI
59%
Loosely correlated
-4.97%
LYEL - XBI
57%
Loosely correlated
+1.62%
LGND - XBI
56%
Loosely correlated
-0.03%
MGNX - XBI
55%
Loosely correlated
-1.01%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BNDD97.220.90
+0.94%
Quadratic Deflation ETF (BNDD)
UNL5.470.03
+0.55%
United States 12 Month Natural Gas Fund LP (UNL)
SCHJ24.240.08
+0.33%
Schwab 1-5 Year Corporate Bond ETF (SCHJ)
VYM153.87-3.23
-2.06%
Vanguard High Dividend Yield Index ETF (VYM)
BFOR21.47-0.61
-2.76%
ALPS Barron's 400 ETF (BFOR)